The current management of c-Kit mutation-positive melanoma patients involves enrolment in clinical trials using a c-Kit inhibitor or immunotherapy, and there is minimal data for efficacy of immune-modulators in c-Kit mutant melanomas [26]. Here, KIT is linked to melanoma.